These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12716541)

  • 21. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.
    García de la Hera M; Ferreros I; del Amo J; García de Olalla P; Pérez Hoyos S; Muga R; del Romero J; Guerrero R; Hernández-Aguado I;
    J Epidemiol Community Health; 2004 Nov; 58(11):944-50. PubMed ID: 15483312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral use among active injection-drug users: the role of patient-provider engagement and structural factors.
    Knowlton AR; Arnsten JH; Eldred LJ; Wilkinson JD; Shade SB; Bohnert AS; Yang C; Wissow LS; Purcell DW
    AIDS Patient Care STDS; 2010 Jul; 24(7):421-8. PubMed ID: 20578910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare.
    Tapp C; Milloy MJ; Kerr T; Zhang R; Guillemi S; Hogg RS; Montaner J; Wood E
    BMC Infect Dis; 2011 Apr; 11():86. PubMed ID: 21466704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study.
    Weber R; Huber M; Rickenbach M; Furrer H; Elzi L; Hirschel B; Cavassini M; Bernasconi E; Schmid P; Ledergerber B;
    HIV Med; 2009 Aug; 10(7):407-16. PubMed ID: 19490174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour.
    Smit C; Lindenburg K; Geskus RB; Brinkman K; Coutinho RA; Prins M
    Addiction; 2006 Mar; 101(3):433-40. PubMed ID: 16499516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts.
    McGowan CC; Weinstein DD; Samenow CP; Stinnette SE; Barkanic G; Rebeiro PF; Sterling TR; Moore RD; Hulgan T
    PLoS One; 2011 Apr; 6(4):e18462. PubMed ID: 21541016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of patients infected with HIV through use of injected drugs compared to patients infected through sexual transmission: late presentation, delayed anti-retroviral treatment and higher mortality.
    Suárez-García I; Sobrino-Vegas P; Dalmau D; Rubio R; Iribarren JA; Blanco JR; Gutierrez F; Montero Alonso M; Bernal E; Vinuesa García D; Del Amo J;
    Addiction; 2016 Jul; 111(7):1235-45. PubMed ID: 26890155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users.
    Tun W; Gange SJ; Vlahov D; Strathdee SA; Celentano DD
    Clin Infect Dis; 2004 Apr; 38(8):1167-74. PubMed ID: 15095224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors.
    Murri R; Fantoni M; Del Borgo C; Izzi I; Visonà R; Suter F; Banfi MC; Barchi E; Orchi N; Bosco O; Wu AW
    J Acquir Immune Defic Syndr; 1999 Dec; 22(5):461-6. PubMed ID: 10961607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The opinions of injecting drug user (IDUs) HIV patients and health professionals on access to antiretroviral treatment and health services in Valencia, Spain.
    Garcia de la Hera M; Davo MC; Ballester-Añón R; Vioque J
    Eval Health Prof; 2011 Sep; 34(3):349-61. PubMed ID: 21411470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
    Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
    Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of education on overall and cause-specific mortality in injecting drug users, according to HIV and introduction of HAART.
    Jarrin I; Lumbreras B; Ferreros I; Pérez-Hoyos S; Hurtado I; Hernández-Aguado I
    Int J Epidemiol; 2007 Feb; 36(1):187-94. PubMed ID: 17085455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS.
    Hirsch JD; Gonzales M; Rosenquist A; Miller TA; Gilmer TP; Best BM
    J Manag Care Pharm; 2011 Apr; 17(3):213-23. PubMed ID: 21434698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Access to HAART and utilization of inpatient medical hospital services among HIV-infected patients with co-occurring serious mental illness and injection drug use.
    Himelhoch S; Chander G; Fleishman JA; Hellinger J; Gaist P; Gebo KA
    Gen Hosp Psychiatry; 2007; 29(6):518-25. PubMed ID: 18022045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late initiation of HAART among HIV-infected patients in Spain is frequent and related to a higher rate of virological failure but not to immigrant status.
    Pérez-Molina JA; Suárez-Lozano I; Del Arco A; Teira R; Bachiller P; Pedrol E; Martínez-Alfaro E; Domingo P; Mariño A; Ribera E; Antela A; de Otero J; Navarro V; González-García J;
    HIV Clin Trials; 2011; 12(1):1-8. PubMed ID: 21388936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pneumocystis jirovecii pneumonia in HIV-1-infected patients in the late-HAART era in developed countries.
    Llibre JM; Revollo B; Vanegas S; Lopez-Nuñez JJ; Ornelas A; Marin JM; Santos JR; Marte P; Morera M; Zuluaga P; Tor J; Clotet B
    Scand J Infect Dis; 2013 Aug; 45(8):635-44. PubMed ID: 23547568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
    Wood E; Hogg RS; Lima VD; Kerr T; Yip B; Marshall BD; Montaner JS
    JAMA; 2008 Aug; 300(5):550-4. PubMed ID: 18677027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of injection drug use behavior on reported antiretroviral therapy use among women in the HIV Epidemiology Research study: on-site versus referral care.
    Rompalo AM; Shah N; Mayer K; Schuman P; Klein RS; Smith DK; Vlahov D
    J Acquir Immune Defic Syndr; 2001 Sep; 28(1):28-34. PubMed ID: 11579274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of case management on unmet needs and utilization of medical care and medications among HIV-infected persons.
    Katz MH; Cunningham WE; Fleishman JA; Andersen RM; Kellogg T; Bozzette SA; Shapiro MF
    Ann Intern Med; 2001 Oct; 135(8 Pt 1):557-65. PubMed ID: 11601927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.